Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$133.34 USD

133.34
1,015,004

+0.26 (0.20%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $133.39 +0.05 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sarepta Down on Reports of FDA Almost Rejecting DMD Gene Therapy

Per a Stat News article, the FDA initially considered rejecting Sarepta's (SRPT) regulatory filing seeking FDA's accelerated approval for DMD gene therapy.

Sarepta Therapeutics (SRPT) Down 6.2% Since Last Earnings Report: Can It Rebound?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock?

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001

Sarepta Therapeutics' (SRPT) shares plunged almost 20% as the FDA decides to hold an advisory meeting for the BLA of its lead gene therapy candidate SRP-9001.

Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up

Sarepta (SRPT) delivers decent fourth-quarter 2022 results. Management confirms that the FDA does not plan to hold an advisory committee meeting for the DMD gene-therapy filing.

Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 3.12% and 3.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More

Let us look at four drug and biotech companies, NVAX, IOVA, ALLO, SRPT and FATE, which are gearing up for their earnings release.

Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Tops Revenue Estimates

Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -36.11% and 19.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Should iShares Morningstar SmallCap Growth ETF (ISCG) Be on Your Investing Radar?

Style Box ETF report for ISCG

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review

The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.

Should iShares Morningstar SmallCap ETF (ISCB) Be on Your Investing Radar?

Style Box ETF report for ISCB

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates

Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales. Shares decline in after-market trading post the announcement.

Sarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -142.98% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Fulcrum Therapeutics, Inc. (FULC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Fulcrum Therapeutics, Inc. (FULC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.